Stock NAMS FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

Real-time Estimate Tradegate
Other stock markets
 21:00:01 17/05/2024 BST 		5-day change 1st Jan Change
18.45 EUR -6.87% Intraday chart for Frazier Lifesciences Acquisition Corporation -9.38% +77.35%
05-15 TD Cowen Starts NewAmsterdam Pharma With Buy Rating MT
05-09 Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
TD Cowen Starts NewAmsterdam Pharma With Buy Rating
MT
Scotiabank Starts NewAmsterdam Pharma With Sector Outperform Rating, $35 Price Target
MT
RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk
MT
Guggenheim Starts NewAmsterdam Pharma With Buy Rating, $30 Price Target
MT
RBC Initiates NewAmsterdam Pharma at Outperform With Speculative Risk Qualifier, $25 Price Target
MT
Credit Suisse Lifts NewAmsterdam Pharma's Price Target to $22 From $21, Keeps Outperform Rating
MT
Credit Suisse Starts NewAmsterdam Pharma at Outperform With $21 Price Target
MT
SVB Securities Initiates Coverage on NewAmsterdam Pharma With Outperform Rating, $19 Price Target
MT
SVB Securities Starts NewAmsterdam Pharma at Outperform With $19 Price Target
MT
William Blair Starts NewAmsterdam Pharma at Outperform
MT
Jefferies Starts NewAmsterdam Pharma at Buy With $24 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NAMS Stock
  4. News Frazier Lifesciences Acquisition Corporation
  5. Analyst Reco.